Media ReleasesArovella Therapeutics

View All Arovella Therapeutics News

Arovella Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report

MELBOURNE, AUSTRALIA 27 October 2023: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment, today releases its Appendix 4C for the first quarter of FY24.

During the quarter, Arovella continued to advance its iNKT cell therapy towards first-in-human clinical trials. Arovella’s technology provides key advantages over existing CAR-T cell therapies and has the potential to be applied to both blood cancers and solid tumours.

Arovella is in a solid financial position with pro-forma cash and cash equivalents of $5.32 million as at 30 September 2023. In addition, the Company expects to receive its R&D rebate of approximately $2 million in Q4 CY23 to add to these funds, further extending its ability to fund its projects.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?